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Abstract: The gut microbiota has emerged as a key factor in the pathogenesis of intestinal viruses,
including enteroviruses, noroviruses and rotaviruses (RVs), where stimulatory and inhibitory effects
on infectivity have been reported. With the aim of determining whether members of the microbiota
interact with RVs during infection, a combination of anti-RV antibody labeling, fluorescence-activated
cell sorting and 16S rRNA amplicon sequencing was used to characterize the interaction between
specific bacteria and RV in stool samples of children suffering from diarrhea produced by G1P[8]
RV. The genera Ruminococcus and Oxalobacter were identified as RV binders in stools, displaying
enrichments between 4.8- and 5.4-fold compared to samples nonlabeled with anti-RV antibodies.
In vitro binding of the G1P[8] Wa human RV strain to two Ruminococcus gauvreauii human isolates was
confirmed by fluorescence microscopy. Analysis in R. gauvreauii with antibodies directed to several
histo-blood group antigens (HBGAs) indicated that these bacteria express HBGA-like substances on
their surfaces, which can be the target for RV binding. Furthermore, in vitro infection of the Wa strain
in differentiated Caco-2 cells was significantly reduced by incubation with R. gauvreauii. These data,
together with previous findings showing a negative correlation between Ruminococcus levels and
antibody titers to RV in healthy individuals, suggest a pivotal interaction between this bacterial group
and human RV. These results reveal likely mechanisms of how specific bacterial taxa of the intestinal
microbiota could negatively affect RV infection and open new possibilities for antiviral strategies.
Keywords: rotavirus; gut microbiota; Ruminococcus
1. Introduction
Despite vaccination, group A rotavirus (RV) continues to be the leading etiologic agent
of viral gastroenteritis in infants and young children worldwide [1] and is responsible for an
estimated 130,000 deaths each year, mostly in developing countries [2]. A traditional dual-
classification system of group A RV based on virion outer capsid proteins establishes more
than 36 different G serotypes (depending on VP7 glycoprotein) and 51 P-types (depending
on VP4 protease-sensitive protein) [3,4]. However, G1P[8], G2P[4], G3P[8] and G4P[8]
RV are prevalent (over 90%) in most countries [5]. RV–host attachment is mediated by
binding of the N-terminal portion of VP4 (VP8* fragment) to glycoconjugates at the cell
surface. Diverse interactions between histo-blood group antigens (HBGA) and VP8* have
been described, and, recently, the reported differences in the recognition of the fucosylated
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secretory H type-1 antigen versus its nonfucosylated precursor in the predominant P[8]
group have explained the altered incidence of RV infections in secretor and nonsecretor
individuals [6,7].
In the complex gut ecosystem where RVs develop, several interplays between the
resident microbiota, the host glycobiology (e.g., mucosal HBGA) and enteric viruses have
been described [6]. The classical view establishes that the gut microbiota protects against
intestinal viral infections, but recent evidence also demonstrated a positive role for the
microbiota in viral infection. Polioviruses and other intestinal viruses rely on the intestinal
microbiota for infection by exploiting microbial-derived substances (e.g., lipopolysaccha-
ride and peptidoglycan) to increase virion stability or to enhance attachment to host cells [8].
According to this, reduced viral infection is observed in gnotobiotic- or antibiotic-treated
animal models [8–11], a situation that has also been observed for RV in a mouse model [11].
Some probiotic and commensal gut bacteria have the ability to in vitro bind RV and human
noroviruses [12–15], and HBGA-like substances have been detected on the surface of enteric
species such as Enterobacter cloacae [13], Enterobacter faecium, Klebsiella spp., Citrobacter spp.
and Hafnia alvei [16]. The bacterium E. cloacae enhanced norovirus infectivity in gnotobiotic
mice and in an in vitro model of infection in human B cells [10]. However, its application
in gnotobiotic pigs reduced norovirus infectivity [17], for which some controversy still
exists in this respect. The dual role of the microbiota in enteric virus infectivity (promoting
or restricting) suggests that some microorganisms can be considered risk factors while
others can lead to protection against infection. In agreement with this concept, diverse
bacterial groups have been correlated to diminished or increased antibody titers (reflecting
previous infections) against RV and norovirus [18]. An important breakthrough has been
recently achieved after identifying that segmented filamentous bacteria (SFB), a group of
microorganisms present in rodents and other vertebrates, and intimately associated with
the intestinal epithelium, protect mice against RV [19].
Due to the increasing evidence of gut microbiota implication in RV infection, the
aim of this work was to investigate which bacteria interact with RV during natural infant
infections and their likely role in the process.
2. Results
2.1. Determination of Rotavirus Binding Bacteria by 16S rDNA Sequencing
By using FACS coupled with a FITC-labeled anti-RV antibody, we identified bacteria
interacting with RV in stool samples from five children suffering from RV diarrhea, clinically
diagnosed as originating from the G1P[8] genotype. Total DNA was isolated from both
sorted bacterial subpopulations (those RV-positive and RV-negative), and their microbial
composition was determined by 16S rDNA sequencing. The information at the genus level
was selected to analyze the differences in relative abundances of each bacterial group in
the RV-binding and nonbinding bacteria. The Ruminococcus genus was identified as a RV
binder, with percentages of abundance in the fluorescent versus the nonfluorescent bacterial
groups showing a ratio of >5, followed by Oxalobacter, which presented a ratio of >4
(Figure 1). However, variability between samples was very high and the differences
were mainly due to individual samples. In particular, samples from two different in-
dividuals accounted for most of the differences in Ruminococcus and Oxalobacter in the
detected microbiotas.
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Figure 1. Increase in the relative abundance of several bacterial taxa at the genus level in the
fluorescent channel of FITC-labeled bacteria (rotavirus-bound) compared to nonlabeled bacteria.
2.2. Ruminococcus Gauvreauii Binds Rotavirus In Vitro
The fact that the sequencing results revealed Ruminococcus as a bacterial genus with
potential for RV binding attracted our attention for two different reasons: (i) this genus was
previously linked to lower anti-RV antibody titers in adult humans [18], and (ii) the species
Ruminococcus gauvreauii has recently been isolated from the human gall bladder [20]. We
therefore analyzed the RV–Ruminococcus interaction using two strains of R. gauvreauii: the
DSM-19829-type strain, isolated from human feces, and the IPLA-NM1 strain, a human bile
isolate [20]. As a RV strain, we utilized Wa, a G1P[8] culture-adapted human RV with the
same genotype as the pathogen present in the selected diarrheal samples. Both bacterial
strains were able to bind Wa RV, as determined by fluorescence microscopy. The binding of
RV to the R. gauvreauii DSM-19829 strain is shown in Figure 2. Interestingly, adding RV to
the bacterial samples also favored a certain degree of bacterial clumping, indicating that
bacteria agglutination can be induced with RV.
2.3. R. gauvreauii Expresses HBGA-Like Substances on Its Surface
An ELISA assay was settled to determine whether RV-binding R. gauvreauii expresses
HBGA-like substances on its surface, providing a mechanism for bacteria–RV physical
interaction (Figure 3). Interestingly, the antibodies against the blood groups A and B
and against the H-antigen and the Lewisa antigen resulted positive for both R. gauvreauii
strains tested (DSM-19829 and IPLA-NM1) as well as for the positive control E. cloacae
ATCC 13047. No signal was detected with the anti-Lewisb antibody. The performance
of this antibody was confirmed in an ELISA with saliva from a Lewisb-positive secretor
individual, as previously described [21], confirming that the bacteria did not express
Lewisb-like substances on their surfaces. Interestingly, the ELISA results showed higher
signals for some HBGA in R. gauvreauii strains compared to E. cloacae.
2.4. R. gauvreauii Interferes with Rotavirus Infection In Vitro
Once the interaction between R. gauvreauii and RV was confirmed, the antiviral prop-
erties of this bacterium were tested. An infection assay was then carried out, in which
the bacteria were preincubated with the cell monolayers before RV infection to simulate
a natural infection, where the bacteria are pre-existing in the mucosal surface. Under
these conditions, it was determined that R. gauvreauii IPLA-NM1 attaches to the Caco-2-
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cell-differentiated monolayer (Figure 4A), and a threefold decrease in Wa RV infectivity
(measured as viral genome equivalents/mL of cell culture supernatants after infection)
was found, demonstrating anti-RV activity for this bacterium (Figure 4B).




Figure 2. Microscopy images showing the interaction between bacteria from the genus Ruminococcus and rotavirus (RV) 
by fluorescence microscopy. Bacteria were incubated with the G1P[8] rotavirus strain Wa or without rotavirus (control), 
and images were collected in the polarized field and in green fluorescence. Merged images from both fields are also pre-
sented. The bars included as a reference possess a size of 10 μm. 
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Figure 3. Histo-blood group antigens (HBGA)-like substances on the Ruminococcus surface detected by ELISA. Ruminococ-
cus gauvreauii strains (DSM-19829 in purple and IPLA-NM1 in blue) and Enterobacter cloacae (positive control in light blue) 
were recognized by anti-A, anti-B, anti-H and anti-Lewisa antibodies, indicating that these bacteria express HBGA-like 
substances on their surfaces. Neg.: negative control (no antibody). Statistical significance (p < 0.05) compared to the nega-
tive control is indicated by asterisks (*). 
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Once the interaction between R. gauvreauii and RV was confirmed, the antiviral prop-
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bacteria were preincubated with the cell monolayers before RV infection to simulate a 
natural infection, where the bacteria are pre-existing in the mucosal surface. Under these 
conditions, it was determined that R. gauvreauii IPLA-NM1 attaches to the Caco-2-cell-
differentiated monolayer (Figure 4A), and a threefold decrease in Wa RV infectivity 
(measured as viral genome equivalents/mL of cell culture supernatants after infection) 
was found, demonstrating anti-RV activity for this bacterium (Figure 4B). 
 
Figure 4. Ruminococcus gauvreauii and in vitro Wa infectivity. (A) R. gauvreauii IPLA-NM1 cells bound to the Caco-2 mon-
olayer. Cells and bacteria were stained with DAPI, and several Z-stack images were taken and processed, as described in 
the Materials and Methods section (Section 4). Caco-2 nuclei are in blue, and R. gauvreauii cells are in green. (B) Inhibitory 
















Figure 3. Histo-blood group antigens (HBGA)-like substances on the Ruminococcus surface
detected by ELISA. Ruminococcus gauvreauii strains (DSM-19829 in purple and IPLA-NM1
in blue) and Enterobacter cloacae (positive control in light blue) were recognized by nti-A,
anti-B, anti-H and anti-Lewisa antibodies, indicating that these bacteria express HBGA-like
substances on their surfaces. Neg.: negative control (no antibody). Statistical significance
(p < 0.05) compared to the negative control is indicated by asterisks (*).
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Figure 4. Ruminococcus gauvreauii and in vitro Wa infectivity. (A) R. gauvreauii IPLA-
NM1 cells bound to the Caco-2 monolayer. Cells and bacteria were stained with DAPI,
and several Z-stack images were taken and process d, as e cribed in he Materials and
Methods section (Section 4). Caco-2 nuclei are in blue, and R. gauvreauii cells are in green.
(B) Inhibitory effect of preincubation of R. gauvreauii on Wa rotavirus infection measured
as the reduction in viral genome equivalents in supernatants of Caco-2 cells after infection.
Statistical significance (p < 0.05) compared to the negative control is indicated by asterisk (*).
3. Discussion
Since the demonstration that the microbiota plays a key role in the infection of viruses
targeting the intestine [8,22], much effort has been made to determine the role of gut
bacteria in the relevant gastroenteritis-producing viruses, rotavirus and norovirus [6].
Unfortunately, despite the importance of this new concept, much of the evidence on
the contribution of bacteria to RV infectivity has been achieved in cellular and animal
models. Correlations between the abundance of several bacterial taxa and diminished
antibody titers to norovirus and RV in adults have been reported [18], but data from
infections in the relevant children group are still scarce and mainly derived from the
results of seroconversion after vaccination with RV vaccine strains [23,24]. In this work,
we contribute to filling this gap through the utilization of clinical samples from children
with acute RV diarrhea. Using these samples, we identified Ruminococcus and Oxalobacter
as two bacterial genera interacting with RV during diarrhea in two separate samples.
One objection that could be argued against the idea that intestinal bacteria regulate the
infectivity of RV is related to the different compartmentalization of RV replication and the
intestinal microbiota. It is known that the gut microbiota mainly resides in the colon, while
RV replication occurs in the small intestine [3], where bacterial numbers and diversity
are much lower compared to the colon [25]. Ruminococcus and Oxalobacter are strictly
anaerobic bacteria associated with the intestinal tract of mammals, and they can be isolated
from human feces, indicative of a colonic habitat [26,27]. Ruminococcus species have been
associated with the important function of degrading resistant starch from food [28,29],
and they are important in the maturation of the intestinal microbiota during human
development [30]. Oxalobacter is important for the metabolism of calcium oxalate in the
intestine [31]. However, Ruminococcus has proved to reside also in the small intestine
and gallbladder, as it can be isolated from bile [20]. The discovery of a Ruminococcus–RV
interaction also coincided with the fact that intestinal Ruminococcus levels were shown
to negatively correlate with IgA titers against RV [18]. We demonstrated P[8] RV surface
binding in R. gauvreauii. This surface attachment can be the basis for the observed inhibitory
effect of R. gauvreauii on the in vitro infectivity of the Wa RV strain. It was previously shown
that enteric bacteria such as E. cloacae express A-, B- and H-like antigens on their surfaces
and are able to bind human norovirus [13]. The same pattern of HBGA-like antigens was
detected on the R. gauvreauii surface. The predominant P[8] RV interacted with the H type-1
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antigen and A-type HBGA, while Lewis antigens were reported not to fit the binding site
for these antigens [32]. However, a recent report pointed to a second carbohydrate-binding
pocket for Lewisb in this viral genotype [33]. H type-1 antigen and A-type HBGA binding
could provide a mechanism by which RVs attach to the R. gauvreauii surface, suggesting that
virus–bacteria adhesion could produce sequestration of viruses that impair viral infectivity.
Previous experiments have shown a reduction in rotavirus infectivity in a similar setup as
described here, such as, for instance, Lactobacillus and Bifidobacterium in Wa [34,35] or bovine
RV infection in culture cells [36]. It has been recently shown that the chronic RV infection
usually present in immunocompromised mice lacking B and T cells (Rag1-KO mice) can be
prevented through ileal colonization by segmented filamentous bacteria (SFB; Candidatus
Arthromitus) [19]. This protective effect does not involve immunoregulatory mechanisms
triggered by SFB but probably depends on two nonmutually exclusive mechanisms: direct
reduction of RV infectivity as a result of contact with SFB and enhanced enterocyte turnover.
A recent study in a mouse model also evidenced a different role in RV infectivity for some
bacterial groups. Infection by RV produces a shift in nutrient availability in the gut and
induces goblet cells to release mucin, which promotes the growth of mucin-degrading
Bacteroides and Akkermansia members in mice ileum. The consumption of mucin by these
bacteria may, in turn, decrease the protection exerted by mucin against RV infection [37].
It is not known at this stage whether high Ruminococcus levels represent a protective
factor against RV infection in children. In fact, samples where Ruminococcus were detected
derived from children suffering from diarrhea. Nevertheless, Ruminococcus members are
frequently found in the feces of children less than five years of age [38]. In a recent study,
the microbiota in the feces from children suffering from RV diarrhea and those from healthy
children were compared, and Ruminococcus was found significantly more abundant in
healthy children, reinforcing the idea of a possible antiviral role of this bacterial genus [39]
and confirming our previous RV–microbiota correlation studies [18].
More studies are needed to unravel the contribution of specific microbiota taxons to RV
infection in humans. Some works have pointed to the relevance of differences in intestinal
microbiota composition on the lack of efficacy (low vaccine take) of RV vaccines, a live viral
vaccine, in low-income and middle-income settings [23,24], but this issue is far from being
solved, and other possible contributing factors have been hypothesized [40]. Nevertheless,
the bacteria–RV interacting pair here reported appears to be biologically relevant since
the interaction was detected in natural infections and correlation of Ruminococcus–RV
susceptibility was previously evidenced in human samples [18]. Our data constitute new
insights into the bacteria-enteric viruses’ interplay during infection and could open new
avenues for exploring innovative strategies to prevent and treat RV infections.
4. Materials and Methods
4.1. Rotavirus Detection and Genotyping
Stool samples from children younger than 5 years with diarrhea, who were admitted
to the Hospital Clínico Universitario de Valencia in 2015, that resulted positive for RV via
immunochromatography (Certest Biotec) were selected for genotyping. The genotyping
of G and P genotypes of samples was performed following the European Network Euro-
RotaNet procedures (www.eurorotanet.com). Five stool samples with the G1P[1] genotype
were selected and stored at −80 ◦C for further processing.
4.2. Preparation of Microbiota Samples from Stools and Cell Sorting
For detecting RV-binding bacteria, we followed a strategy similar to that recently
described to quantify the in vitro binding of noroviral-virus-like particles to gut commensal
bacteria [41]. Two-hundred milligrams of each stool sample was suspended in 1 mL of
0.9% saline solution (SS) by pipetting, followed by 10 s vortexing. The suspensions were
centrifuged at 2000× g for 2 min to remove coarse materials, and the supernatants were
further centrifuged at 12,000× g for 5 min to pellet the bacteria. The pelleted bacteria were
washed twice in 1 mL of SS. The washed pellets were resuspended in 300 µL of SS and
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fixed by adding 1200 µL of 4% paraformaldehyde overnight at 4 ◦C. After fixation, the
cells were washed 3 times with SS and finally resuspended in 1 mL of SS. One-hundred
microliters were reserved to study the sample autofluorescence in the flow cytometer, and
the other 900 µL were further processed for RV immunostaining. The cells were pelleted
and suspended in 150 µL of SS containing 5% bovine serum albumin (BSA) (Sigma-Aldrich,
St. Louis, MO, USA) for 1 h at 37 ◦C to prevent nonspecific antibody binding. After blocking,
1.5 µL of FITC-labeled goat anti-RV antibody (ab31435, Abcam) was added and incubated
for 1 h at 37 ◦C. After RV labeling, 1.5 µL of a 1 mg/mL solution of propidium iodide
(Thermo Fisher, Waltham, MA, USA) was added and incubated for 30 min at 37 ◦C for
nucleic acid staining. Finally, the cells were pelleted, washed twice with SS and resuspended
in 1 mL of SS.
Bacterial cells were sorted using a cytometer FACSAria™III Cell and BD FACSDiva
v6.1.6 analysis software (BD Biosciences, San Jose, CA, USA) equipped with a two-laser
system at 488 nm and 633 nm (Figure 5). Cell sorting was performed with a 70 µm
nozzle. Microorganisms were determined using forward- and side-scatter parameters (FSC
and SSC). A FITC detector (530/30 nm bandpass filter) was used to determine the levels
of labeled bacteria (RV binders) and propidium iodide, and a PE detector (585/42 nm
bandpass filter) was used to check for the presence of DNA. The parameter settings used
comprised a SSC signal at 200 units as the threshold to define an event to be counted and
voltages of FSC, SSC, FITC and PE of 16, 308, 350 and 455, respectively.
Figure 5. Fluorescence-activated cell sorting of rotavirus-bound fecal microbiota. Nonlabeled bacteria
from the stools of patients were subject to FACS for determining autofluorescence and establishing
the nonbinding population (A,B). The same bacteria were labeled with FITC-anti-rotavirus and
subject to FACS (C,D). The P6 population contained the non-FITC fluorescent bacteria, and the P11
population contained the FITC fluorescent bacteria with the bound rotavirus. The bacteria (labeled
and nonlabeled) were collected separately and analyzed by 16S rDNA sequencing.
4.3. Sorted Fractions DNA Extraction and 16S rDNA Sequencing
Total DNA was isolated from the sorted bacteria by using the MasterPure Complete
DNA & RNA Purification Kit (Epicentre) with a previous enzymatic step with 20 mg/mL
of lysozyme (Roche) and 10 U/mL of mutanolysin (Sigma) at 37 ◦C for 1 h, followed by
glass bead beating (0.17 mm diameter) for 1 min at 4 ◦C. The obtained DNA was am-
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plified with the TruePrime WGA kit (Sygnis), following the manufacturer’s instructions.
Total DNA concentration was measured and normalized using a Qubit® 2.0 Fluorometer
(Life Technology, Carlsbad, CA, USA). Subsequently, the V3-V4 region of the bacterial 16S
rDNA gene was amplified by PCR using Illumina adapter overhang nucleotide sequences,
following Illumina protocols. After 16S rDNA gene amplification, a multiplexing step
was performed with the Nextera XT Index kit (Illumina, San Diego, CA, USA). Amplicons
were checked with a Bioanalyzer DNA 1000 chip, and libraries were sequenced using
a 2 × 300 bp paired-end run (MiSeq Reagent kit v3) on a MiSeq-Illumina platform (FIS-
ABIO Sequencing Service, Valencia, Spain). Controls during PCR amplification were also
included and sequenced.
4.4. Bioinformatics and Statistical Analysis
Raw reads were searched for residual adaptors using the Trimmomatic program [42].
Artifacts, a quality check and quality trimming were performed with the prinseq-lite
program [43]. R1 and R2 fastq reads were then joined using overlapping reads with
the FLASH program [44]. The quality-filtered sequences were checked for chimera, and
the nonchimeric sequences were processed using a QIIME pipeline (version 1.9.0) [45].
The sequences were clustered at 97% identity into operational taxonomic units (OTUs),
and representative sequences were taxonomically classified based on the Greengenes 16S
rRNA gene database (version 13.8). Sequences that could not be classified to the domain
level or were classified as cyanobacteria and chloroplasts were removed from the dataset.
Subsequently, to study the RV–microbiota interaction patterns, the threshold used for
including the genera was 0.5% or greater in relative abundance in either the RV-positive
or RV-negative fractions. The abundance of proportions of the given genera was log-
transformed before calculating the ratio between the RV-positive or RV-negative fractions,
resulting in the RV index. The index (calculated according to the formula log(RV++/RV−))
score reflects the degree of virus responsiveness and interaction to the specific microbial
members, where the positive values represent the genera predominantly found to interact
closely with RV, and the negative values represent the bacterial genera predominantly not
interacting with RV. Calypso software (http://cgenome.net/calypso/) was used with total
sum normalization (TSS) for the statistical analysis.
4.5. Bacterial Strains and Culture Conditions
R. gauvreauii DSM-19829 and R. gauvreauii IPLA-NM1 [20] strains were used in this
study. R. gauvreauii DSM-19829 was purchased from the DSMZ Collection, and the IPLA-
NM1 strain was isolated from a human bile sample [20]. They were grown in Gifu Anaero-
bic Medium (Nissui) supplemented with 0.25% (w/v) L-cysteine (Sigma-Aldrich) (named
GAMc) incubated at 37 ◦C for 72 h in a Whitley MG500 anaerobic cabinet (Don Whitley
Scientific) under a 10% H2, 10% CO2 and 80% N2 gas atmosphere. The two strains were
routinely maintained by growing in 2% agar GAMc plates under anaerobic conditions.
4.6. Production of Rotavirus Infectious Viral Particles
The RV Wa strain, G1P[8], was cultured in MA104 cells and purified, as previously
described [32]. Briefly, 10 confluent 150 cm2 flasks (approximately 1.5 × 107 cells/flask)
were infected with the Wa strain at a multiplicity of infection (MOI) of ≤0.1. One-hundred
milliliters of medium with 1.5 × 108 virus/mL were obtained, and the viral particles
were concentrated by pelleting at 160,000× g for 1 h at 4 ◦C in an SW 41 rotor (Beckman).
The viral pellet was resuspended in TNC buffer (20 mM Tris-HCl pH 8.0, 100 mM NaCl,
1 mM CaCl2) for obtaining triple-layered particles, and the particles were visualized by
transmission electron microscopy after negative staining with phosphotungstic acid.
4.7. Ruminococcus–Rotavirus Binding Assay
Cells from Ruminococcus gauvreauii DSM-19829 and R. gauvreauii IPLA-NM1, an isolate
from the human small intestine [20], were washed and diluted in PBS to an OD595 of 1. The
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cells were incubated with RV Wa at a concentration of 100 µg/mL of total viral antigen for
1 h at 37 ◦C with gentle agitation to allow the bacteria to interact with the virus in a final
volume of 200 µL. After this period, the cells were centrifuged and washed two times with
PBS to remove any unbound RV. The cells were resuspended in 200 µL of fixing solution
(4% formaldehyde in PBS) and incubated for 15 min at 37 ◦C. After fixing, the bacterial
suspensions were spread on glass microscope slides and air dried. The slides were blocked
for 1 h at room temperature in PBS containing 1% BSA, and the viruses were detected by
incubation with a mouse anti-RV IgG antibody raised in the laboratory, followed by an
AlexaFluor488-labeled goat antimouse IgG antibody (1:400, Molecular Probes, Eugene, OR,
USA). The preparations were mounted with 10 µL of the ProLong Gold Antifade Reagent
(Life Technologies, Carlsbad, CA, USA) and visualized with an Eclipse 90i fluorescence
microscope (Nikon, Tokyo, Japan). Controls without the virus and without the primary
antibody (mouse anti-RV) were included.
4.8. HBGA ELISA on Bacterial Cells
An ELISA assay was settled up to determine whether the Ruminococcus strains ex-
pressed HBGA-like substances on their surface. ELISA plates (Costar) were coated with
the two R. gauvreauii strains (DSM-19829 and IPLA-NM1). Enterobacter cloacae ATCC 13,047
(grown in nutrient broth at 37 ◦C overnight with shaking) was used as a positive control
since it was previously determined that it expresses HBGA-like substances at its bacterial
envelope [13]. The bacterial cells were washed three times in PBS and diluted to an OD595 of
1 in PBS. The wells of an ELISA plate were coated with 100 µL of the bacterial suspensions
by incubation at 4 ◦C overnight. After coating, the wells were washed three times with 200
µL PBS containing 0.05% Tween 20 (PBS-T) and blocked with PBS-T containing 3% BSA
for 1 h at 37 ◦C. After blocking, the plate was incubated for 1 h at 37 ◦C with monoclonal
antibodies directed to HBGA (anti-A and anti-B, Diagast; anti-H, anti-Lea and anti-Leb,
Covance, Princeton, NJ, USA) and diluted 1:100 in PBS with 1% BSA. After three washes,
horseradish peroxidase goat antimouse IgG (Sigma) diluted 1:2000 in PBS-T plus 1% BSA
was added and incubated for 1 h at 37 ◦C. After three washes with PBS-T, the reactions
were developed with o-phenylenediamine dihydrochloride (OPD-Fast) (Sigma), stopped
with 2M H2SO4 and recorded at 492 nm. The cut-off value was defined as a threefold
increase in absorbance value compared to the negative control (cells incubated only with
the secondary antibody). All the experiments were performed in triplicate.
4.9. Rotavirus Infection Blocking Assay with R. gauvreauii
Caco-2 cells were placed in 96-well cell culture plates (Costar) at 5 × 104 cells/well in
MEM medium containing 10% fetal bovine serum (FBS), 1% nonessential amino acids and
1× penicillin/streptomycin and allowed to differentiate for 11 days in a CO2 incubator at
37 ◦C, with culture medium changes every three days. After differentiation, cell monolayers
were washed with serum-free medium. R. gauvreauii IPLA-NM1 cells were added at an
OD595 of 0.01 to Caco-2 cells and incubated for 1 h at 37 ◦C. Control wells without added
bacteria were included. Caco-2 monolayers were washed three times with serum-free
medium containing 1 µg/mL of type IX trypsin (Sigma) and infected with activated
rotavirus at 1.5 × 104 genome equivalents/well (Wa RVs were previously activated by
incubation in serum-free medium with type IX trypsin (Sigma) at 10 µg/mL for 30 min at
37 ◦C). RVs were kept in contact with the Caco-2 monolayers for 1 h at 37 ◦C. After this
incubation period, the viral inoculum was removed, and the wells were washed twice
with serum-free medium and incubated with serum-free medium containing 1 µg/mL of
type IX trypsin (Sigma) for 16 h. After this period, the cell monolayers were disrupted
with PBS containing 1% Triton X-100, and RNA was extracted using the Nucleospin-
RNA virus Kit (Macherey-Nagel, Dylan, German), following the supplier instructions.
The RV genome equivalents obtained after infection were calculated by RT-qPCR, as
previously described [46]. Bacterial adhesion to the Caco-2 monolayers was also visualized
by fluorescence. After incubation of the bacterial suspension with the Caco-2 monolayer,
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the cells were fixed and stained with DAPI. Nine 1 µm Z-stack images were taken at
100× using an Eclipse 90i microscope (Nikon Corporation, Tokyo, Japan). These image
stacks were processed with Fiji (ImageJ 1.49q Software, National Institutes of Health, USA)
and subdivided into two stacks, which contained basal visual information of the Caco-2
monolayer (mainly nuclei) and the bacteria located on the top, respectively. Both substacks
were processed separately and finally merged into single images.
5. Conclusions
FACS, together with 16S rDNA NGS, are suitable technologies to unravel the members
of the microbiota that physically interact with human rotaviruses in stool samples from
infected children. Furthermore, bacteria from the genus Ruminococcus express HBGAs
(putative rotavirus receptors) on their surfaces and possess antiviral activity in vitro.
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